2025-01-04 13:47:27,811 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Low" before October 1, 2024?
2025-01-04 13:47:27,811 - INFO - Run 0:
To forecast whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "Low" before October 1, 2024, I will break the problem into tractable sub-problems, balance inside and outside views, and weigh the evidence carefully.

### Step 1: Base Rate Analysis (Outside View)
- Historically, the CDC has maintained a "Very Low" or "Low" risk assessment for mpox in the US general public, even during the 2022 outbreak. The current outbreak in Africa, driven by the more severe clade Ib variant, has not yet resulted in significant spread outside Africa. The CDC's August 14, 2024, rapid risk assessment reaffirms a "Very Low" risk to the US general population, with moderate confidence.
- The base rate for such risk assessments escalating to "Moderate" or higher within a short timeframe (6 weeks) is low, especially given the lack of direct flights from affected regions to the US and the absence of reported cases in the US as of August 23, 2024.

### Step 2: Current Trends and Evidence (Inside View)
- **Evidence for Higher Risk:**
  - The Africa CDC declared mpox a public health emergency of continental security on August 13, 2024, due to a 160% increase in cases and 19% increase in deaths in 2024 compared to 2023.
  - The WHO declared a global public health emergency on August 14, 2024, citing the spread of the clade Ib variant to neighboring countries and its potential for international spread.
  - A case of clade Ib mpox was detected in Sweden, indicating potential for spread to Europe and beyond.
  - The CDC has issued health alerts to clinicians to maintain a heightened index of suspicion for mpox in patients with recent travel to affected regions.

- **Evidence for Lower Risk:**
  - The CDC's August 14, 2024, rapid risk assessment maintains a "Very Low" risk for the US general population, citing limited epidemiologic data, no direct flights from affected regions, and effective public health measures.
  - The European CDC and other health agencies (e.g., Germany, Canada) have assessed the risk to their general populations as "Very Low" or "Low."
  - No cases of clade Ib mpox have been reported in the US as of August 23, 2024.
  - The CDC has a robust surveillance system and is prepared to respond to any changes in the situation.

### Step 3: Balancing Evidence
- While the outbreak in Africa is severe and has prompted global concern, the risk to the US general population remains low due to geographic and epidemiological barriers (e.g., lack of direct flights, low transmission rates outside close-contact settings).
- The CDC's risk assessment is based on current evidence and is unlikely to change significantly unless there is a substantial increase in cases in the US or evidence of sustained community transmission, which is currently absent.
- The timeframe (6 weeks) is short, making a significant escalation in risk assessment unlikely.

### Step 4: Final Forecast
Given the current evidence and historical patterns, the probability of the CDC's risk assessment exceeding "Low" before October 1, 2024, is low. However, there is a small chance of escalation if new cases are detected in the US or if the outbreak spreads more widely in Europe.

**My Prediction: Between 10.00% and 20.00%, but 15.00% being the most likely. Probability: 15.00%.**

2025-01-04 13:47:46,996 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Low" before October 1, 2024?
2025-01-04 13:47:46,996 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Low" before October 1, 2024?
2025-01-04 13:47:46,997 - INFO - Run 1:
To forecast whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "Low" before October 1, 2024, I will follow the superforecasting principles outlined:

### Step 1: Triage and Reference Relevant Predictions
- No specific human predictions from platforms like FiveThirtyEight, Polymarket, or Metaculus are available for this question. However, the CDC's current assessment (as of August 14, 2024) is "Very Low" for the general population, with moderate confidence. This provides a baseline.

### Step 2: Break the Problem into Sub-Problems
- **Current Risk Assessment**: The CDC's current assessment is "Very Low" for the general population.
- **Factors Influencing Risk**: Transmission dynamics, vaccination rates, travel patterns, and global spread.
- **Timeframe**: The question focuses on the period between August 15, 2024, and September 30, 2024.

### Step 3: Balance Inside and Outside Views
- **Inside View**: The CDC's current assessment, recent modeling studies, and global mpox trends.
- **Outside View**: Historical patterns of infectious disease spread, especially zoonotic diseases like mpox.

### Step 4: Balance Under- and Overreacting to Evidence
- The CDC's modeling suggests that household transmission of clade I mpox in the US is unlikely to result in a large number of cases. However, the global spread of the new clade Ib variant in Africa and its detection in Europe (e.g., Sweden) could increase the risk of imported cases.

### Step 5: Identify Clashing Causal Forces
- **Mitigating Factors**: High vaccination rates among at-risk populations (e.g., MSM), limited direct travel from affected regions (DRC and neighboring countries), and effective public health measures.
- **Risks**: The new clade Ib variant is more transmissible and severe, with potential for undetected spread due to low testing capacity in Africa.

### Step 6: Extrapolate Current Trends Linearly
- The current trend shows a significant increase in mpox cases in Africa, but limited spread outside the continent. The risk to the US general population remains low, with no cases of clade I reported in the US as of August 2024.

### Step 7: Distinguish Degrees of Doubt
- The CDC's confidence in its assessment is moderate, indicating some uncertainty. However, the lack of direct flights from DRC to the US and the absence of clade I cases in the US suggest a low likelihood of significant spread.

### Step 8: Balance Under- and Overconfidence
- While the global situation is concerning, the US-specific factors (e.g., vaccination, surveillance, and limited travel) suggest a low probability of the risk exceeding "Low" before October 1, 2024.

### Step 9: Learn from Errors
- Historical patterns show that mpox outbreaks outside Africa have been contained relatively quickly. However, the new clade Ib variant introduces uncertainty, though its impact on the US general population is likely limited.

### Final Assessment
- The CDC's current assessment of "Very Low" risk is unlikely to change significantly before October 1, 2024, given the mitigating factors and limited spread outside Africa. The probability of the risk exceeding "Low" is low.

**My Prediction: Between 5.00% and 15.00%, but 10.00% being the most likely. Probability: 10.00%.**

2025-01-04 13:47:46,997 - INFO - Run 1:
To forecast whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "Low" before October 1, 2024, I will follow the superforecasting principles outlined:

### Step 1: Triage and Reference Relevant Predictions
- No specific human predictions from platforms like FiveThirtyEight, Polymarket, or Metaculus are available for this question. However, the CDC's current assessment (as of August 14, 2024) is "Very Low" for the general population, with moderate confidence. This provides a baseline.

### Step 2: Break the Problem into Sub-Problems
- **Current Risk Assessment**: The CDC's current assessment is "Very Low" for the general population.
- **Factors Influencing Risk**: Transmission dynamics, vaccination rates, travel patterns, and global spread.
- **Timeframe**: The question focuses on the period between August 15, 2024, and September 30, 2024.

### Step 3: Balance Inside and Outside Views
- **Inside View**: The CDC's current assessment, recent modeling studies, and global mpox trends.
- **Outside View**: Historical patterns of infectious disease spread, especially zoonotic diseases like mpox.

### Step 4: Balance Under- and Overreacting to Evidence
- The CDC's modeling suggests that household transmission of clade I mpox in the US is unlikely to result in a large number of cases. However, the global spread of the new clade Ib variant in Africa and its detection in Europe (e.g., Sweden) could increase the risk of imported cases.

### Step 5: Identify Clashing Causal Forces
- **Mitigating Factors**: High vaccination rates among at-risk populations (e.g., MSM), limited direct travel from affected regions (DRC and neighboring countries), and effective public health measures.
- **Risks**: The new clade Ib variant is more transmissible and severe, with potential for undetected spread due to low testing capacity in Africa.

### Step 6: Extrapolate Current Trends Linearly
- The current trend shows a significant increase in mpox cases in Africa, but limited spread outside the continent. The risk to the US general population remains low, with no cases of clade I reported in the US as of August 2024.

### Step 7: Distinguish Degrees of Doubt
- The CDC's confidence in its assessment is moderate, indicating some uncertainty. However, the lack of direct flights from DRC to the US and the absence of clade I cases in the US suggest a low likelihood of significant spread.

### Step 8: Balance Under- and Overconfidence
- While the global situation is concerning, the US-specific factors (e.g., vaccination, surveillance, and limited travel) suggest a low probability of the risk exceeding "Low" before October 1, 2024.

### Step 9: Learn from Errors
- Historical patterns show that mpox outbreaks outside Africa have been contained relatively quickly. However, the new clade Ib variant introduces uncertainty, though its impact on the US general population is likely limited.

### Final Assessment
- The CDC's current assessment of "Very Low" risk is unlikely to change significantly before October 1, 2024, given the mitigating factors and limited spread outside Africa. The probability of the risk exceeding "Low" is low.

**My Prediction: Between 5.00% and 15.00%, but 10.00% being the most likely. Probability: 10.00%.**

2025-01-04 13:48:05,305 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Low" before October 1, 2024?
2025-01-04 13:48:05,305 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Low" before October 1, 2024?
2025-01-04 13:48:05,305 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Low" before October 1, 2024?
2025-01-04 13:48:05,305 - INFO - Run 2:
To forecast whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "Low" before October 1, 2024, I will follow the superforecasting principles outlined:

### Step 1: Triage and Reference Relevant Predictions
- No specific human predictions from platforms like FiveThirtyEight, Polymarket, or Metaculus are available for this question. However, the CDC's current assessment (as of August 14, 2024) is "Very Low" for the general population, with moderate confidence. This provides a baseline.

### Step 2: Break the Problem into Sub-Problems
1. **Current Risk Assessment**: The CDC's current risk assessment is "Very Low" for the general population.
2. **Trends in Mpox Cases**: The outbreak is concentrated in Africa, with limited spread to Europe and no cases reported in the US.
3. **Transmission Dynamics**: The new clade Ib strain is more transmissible and severe, but the US has no direct flights from affected regions, and vaccination efforts are ongoing.
4. **CDC's Monitoring and Response**: The CDC is reviewing evidence every two weeks and has a robust system for detecting and responding to outbreaks.

### Step 3: Balance Inside and Outside Views
- **Outside View**: Historically, mpox outbreaks outside endemic regions (like the US in 2022) have been contained with vaccination and public health measures. The base rate for a "Very Low" risk assessment escalating to "Moderate" or higher within six weeks is low.
- **Inside View**: The current outbreak in Africa is severe, but the US has no reported cases, and the CDC is actively monitoring the situation. The lack of direct flights and high vaccination rates among at-risk populations reduce the likelihood of widespread transmission.

### Step 4: Balance Under- and Overreacting to Evidence
- The Africa CDC has declared a continental emergency, and the WHO has declared a global emergency. However, these declarations are based on the situation in Africa, not the US.
- The CDC's risk assessment is based on US-specific factors, such as travel patterns, vaccination rates, and healthcare infrastructure, which are favorable.

### Step 5: Identify Clashing Causal Forces
- **For Higher Risk**: The new clade Ib strain is more transmissible and severe, and global travel could introduce cases to the US.
- **For Lower Risk**: No cases have been reported in the US, and the CDC is actively monitoring and updating its risk assessment. Vaccination efforts and public health measures are robust.

### Step 6: Extrapolate Current Trends Linearly
- The current trend shows no cases in the US, and the CDC's risk assessment remains "Very Low." Without a significant change in transmission dynamics or case importation, this trend is likely to continue.

### Step 7: Distinguish Degrees of Doubt
- There is a small chance that a case could be imported to the US, but the likelihood of sustained transmission leading to a higher risk assessment is low.

### Step 8: Balance Under- and Overconfidence
- While the situation in Africa is concerning, the US-specific factors make it unlikely that the risk assessment will exceed "Low" before October 1, 2024.

### Step 9: Learn from Errors
- Past mpox outbreaks in the US were contained quickly, suggesting that the CDC's current assessment is reliable. Overreacting to the global emergency declaration would be a mistake.

### Final Reasoning
The CDC's current risk assessment is "Very Low," and there is no evidence to suggest a significant change in the next six weeks. The lack of cases in the US, combined with robust public health measures, makes it unlikely that the risk assessment will exceed "Low" before October 1, 2024.

My Prediction: Between 5.00% and 15.00%, but 10.00% being the most likely. Probability: 10.00%.

2025-01-04 13:48:05,305 - INFO - Run 2:
To forecast whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "Low" before October 1, 2024, I will follow the superforecasting principles outlined:

### Step 1: Triage and Reference Relevant Predictions
- No specific human predictions from platforms like FiveThirtyEight, Polymarket, or Metaculus are available for this question. However, the CDC's current assessment (as of August 14, 2024) is "Very Low" for the general population, with moderate confidence. This provides a baseline.

### Step 2: Break the Problem into Sub-Problems
1. **Current Risk Assessment**: The CDC's current risk assessment is "Very Low" for the general population.
2. **Trends in Mpox Cases**: The outbreak is concentrated in Africa, with limited spread to Europe and no cases reported in the US.
3. **Transmission Dynamics**: The new clade Ib strain is more transmissible and severe, but the US has no direct flights from affected regions, and vaccination efforts are ongoing.
4. **CDC's Monitoring and Response**: The CDC is reviewing evidence every two weeks and has a robust system for detecting and responding to outbreaks.

### Step 3: Balance Inside and Outside Views
- **Outside View**: Historically, mpox outbreaks outside endemic regions (like the US in 2022) have been contained with vaccination and public health measures. The base rate for a "Very Low" risk assessment escalating to "Moderate" or higher within six weeks is low.
- **Inside View**: The current outbreak in Africa is severe, but the US has no reported cases, and the CDC is actively monitoring the situation. The lack of direct flights and high vaccination rates among at-risk populations reduce the likelihood of widespread transmission.

### Step 4: Balance Under- and Overreacting to Evidence
- The Africa CDC has declared a continental emergency, and the WHO has declared a global emergency. However, these declarations are based on the situation in Africa, not the US.
- The CDC's risk assessment is based on US-specific factors, such as travel patterns, vaccination rates, and healthcare infrastructure, which are favorable.

### Step 5: Identify Clashing Causal Forces
- **For Higher Risk**: The new clade Ib strain is more transmissible and severe, and global travel could introduce cases to the US.
- **For Lower Risk**: No cases have been reported in the US, and the CDC is actively monitoring and updating its risk assessment. Vaccination efforts and public health measures are robust.

### Step 6: Extrapolate Current Trends Linearly
- The current trend shows no cases in the US, and the CDC's risk assessment remains "Very Low." Without a significant change in transmission dynamics or case importation, this trend is likely to continue.

### Step 7: Distinguish Degrees of Doubt
- There is a small chance that a case could be imported to the US, but the likelihood of sustained transmission leading to a higher risk assessment is low.

### Step 8: Balance Under- and Overconfidence
- While the situation in Africa is concerning, the US-specific factors make it unlikely that the risk assessment will exceed "Low" before October 1, 2024.

### Step 9: Learn from Errors
- Past mpox outbreaks in the US were contained quickly, suggesting that the CDC's current assessment is reliable. Overreacting to the global emergency declaration would be a mistake.

### Final Reasoning
The CDC's current risk assessment is "Very Low," and there is no evidence to suggest a significant change in the next six weeks. The lack of cases in the US, combined with robust public health measures, makes it unlikely that the risk assessment will exceed "Low" before October 1, 2024.

My Prediction: Between 5.00% and 15.00%, but 10.00% being the most likely. Probability: 10.00%.

2025-01-04 13:48:05,305 - INFO - Run 2:
To forecast whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "Low" before October 1, 2024, I will follow the superforecasting principles outlined:

### Step 1: Triage and Reference Relevant Predictions
- No specific human predictions from platforms like FiveThirtyEight, Polymarket, or Metaculus are available for this question. However, the CDC's current assessment (as of August 14, 2024) is "Very Low" for the general population, with moderate confidence. This provides a baseline.

### Step 2: Break the Problem into Sub-Problems
1. **Current Risk Assessment**: The CDC's current risk assessment is "Very Low" for the general population.
2. **Trends in Mpox Cases**: The outbreak is concentrated in Africa, with limited spread to Europe and no cases reported in the US.
3. **Transmission Dynamics**: The new clade Ib strain is more transmissible and severe, but the US has no direct flights from affected regions, and vaccination efforts are ongoing.
4. **CDC's Monitoring and Response**: The CDC is reviewing evidence every two weeks and has a robust system for detecting and responding to outbreaks.

### Step 3: Balance Inside and Outside Views
- **Outside View**: Historically, mpox outbreaks outside endemic regions (like the US in 2022) have been contained with vaccination and public health measures. The base rate for a "Very Low" risk assessment escalating to "Moderate" or higher within six weeks is low.
- **Inside View**: The current outbreak in Africa is severe, but the US has no reported cases, and the CDC is actively monitoring the situation. The lack of direct flights and high vaccination rates among at-risk populations reduce the likelihood of widespread transmission.

### Step 4: Balance Under- and Overreacting to Evidence
- The Africa CDC has declared a continental emergency, and the WHO has declared a global emergency. However, these declarations are based on the situation in Africa, not the US.
- The CDC's risk assessment is based on US-specific factors, such as travel patterns, vaccination rates, and healthcare infrastructure, which are favorable.

### Step 5: Identify Clashing Causal Forces
- **For Higher Risk**: The new clade Ib strain is more transmissible and severe, and global travel could introduce cases to the US.
- **For Lower Risk**: No cases have been reported in the US, and the CDC is actively monitoring and updating its risk assessment. Vaccination efforts and public health measures are robust.

### Step 6: Extrapolate Current Trends Linearly
- The current trend shows no cases in the US, and the CDC's risk assessment remains "Very Low." Without a significant change in transmission dynamics or case importation, this trend is likely to continue.

### Step 7: Distinguish Degrees of Doubt
- There is a small chance that a case could be imported to the US, but the likelihood of sustained transmission leading to a higher risk assessment is low.

### Step 8: Balance Under- and Overconfidence
- While the situation in Africa is concerning, the US-specific factors make it unlikely that the risk assessment will exceed "Low" before October 1, 2024.

### Step 9: Learn from Errors
- Past mpox outbreaks in the US were contained quickly, suggesting that the CDC's current assessment is reliable. Overreacting to the global emergency declaration would be a mistake.

### Final Reasoning
The CDC's current risk assessment is "Very Low," and there is no evidence to suggest a significant change in the next six weeks. The lack of cases in the US, combined with robust public health measures, makes it unlikely that the risk assessment will exceed "Low" before October 1, 2024.

My Prediction: Between 5.00% and 15.00%, but 10.00% being the most likely. Probability: 10.00%.

2025-01-04 13:48:35,212 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Low" before October 1, 2024?
2025-01-04 13:48:35,212 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Low" before October 1, 2024?
2025-01-04 13:48:35,212 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Low" before October 1, 2024?
2025-01-04 13:48:35,212 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Low" before October 1, 2024?
2025-01-04 13:48:35,212 - INFO - Run 3:
To forecast whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "Low" before October 1, 2024, I will follow the superforecasting principles outlined:

1. **Triage and reference relevant predictions**: No specific human predictions from platforms like FiveThirtyEight, Polymarket, or Metaculus are available for this question, so I will rely on the provided data and historical patterns.

2. **Break the problem into sub-problems**:
   - What is the current CDC assessment of mpox risk to the US general public?
   - What factors could cause the CDC to revise its risk assessment upward?
   - What is the likelihood of these factors occurring before October 1, 2024?

3. **Balance inside and outside views**:
   - **Outside view**: Historically, the CDC has maintained a "Very Low" or "Low" risk assessment for mpox in the US general population, even during the 2022 outbreak. The current outbreak in Africa, while severe, has not yet led to significant spread outside the continent.
   - **Inside view**: The new clade Ib variant is more transmissible and severe, but the US has no direct flights from the DRC, and the CDC has assessed the risk as "Very Low" with moderate confidence. The US also has a robust public health infrastructure and vaccination programs in place.

4. **Balance under- and overreacting to evidence**:
   - The Africa CDC has declared a public health emergency of continental security, and the WHO has declared a global public health emergency. However, the CDC's assessment remains "Very Low" for the US general population.
   - The European CDC and other health agencies have assessed the risk to their general populations as "Very Low" or "Low," suggesting a low likelihood of significant spread to the US.

5. **Clashing causal forces**:
   - **Forces increasing risk**: The new clade Ib variant is more transmissible and severe, and there is a risk of imported cases. The outbreak in Africa is worsening, with increasing cases and deaths.
   - **Forces decreasing risk**: The US has no direct flights from the DRC, and the CDC has robust surveillance and response systems. Vaccination coverage among high-risk groups in the US is relatively high.

6. **Extrapolate current trends linearly**:
   - The current trend shows a worsening outbreak in Africa but no significant spread to the US. The CDC has not indicated any imminent change in its risk assessment.

7. **Distinguish degrees of doubt**:
   - There is a small but non-zero chance that the situation could change rapidly, such as if a case is detected in the US or if the outbreak spreads to countries with more travel connections to the US.

8. **Balance under- and overconfidence**:
   - While the current risk is low, the possibility of a rapid change in the situation warrants some caution. However, the likelihood of the CDC revising its assessment to "Moderate" or higher before October 1, 2024, is low.

9. **Look for errors behind mistakes**:
   - Overestimating the risk based on the severity of the outbreak in Africa without considering the US's specific context could lead to an overconfident prediction.

**Conclusion**: Based on the current CDC assessment, the lack of significant spread outside Africa, and the US's robust public health infrastructure, the likelihood of the CDC revising its risk assessment to exceed "Low" before October 1, 2024, is low. However, the possibility of imported cases or a rapid change in the situation warrants a small probability.

My Prediction: Between 5.00% and 15.00%, but 10.00% being the most likely. Probability: 10.00%.

2025-01-04 13:48:35,212 - INFO - Run 3:
To forecast whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "Low" before October 1, 2024, I will follow the superforecasting principles outlined:

1. **Triage and reference relevant predictions**: No specific human predictions from platforms like FiveThirtyEight, Polymarket, or Metaculus are available for this question, so I will rely on the provided data and historical patterns.

2. **Break the problem into sub-problems**:
   - What is the current CDC assessment of mpox risk to the US general public?
   - What factors could cause the CDC to revise its risk assessment upward?
   - What is the likelihood of these factors occurring before October 1, 2024?

3. **Balance inside and outside views**:
   - **Outside view**: Historically, the CDC has maintained a "Very Low" or "Low" risk assessment for mpox in the US general population, even during the 2022 outbreak. The current outbreak in Africa, while severe, has not yet led to significant spread outside the continent.
   - **Inside view**: The new clade Ib variant is more transmissible and severe, but the US has no direct flights from the DRC, and the CDC has assessed the risk as "Very Low" with moderate confidence. The US also has a robust public health infrastructure and vaccination programs in place.

4. **Balance under- and overreacting to evidence**:
   - The Africa CDC has declared a public health emergency of continental security, and the WHO has declared a global public health emergency. However, the CDC's assessment remains "Very Low" for the US general population.
   - The European CDC and other health agencies have assessed the risk to their general populations as "Very Low" or "Low," suggesting a low likelihood of significant spread to the US.

5. **Clashing causal forces**:
   - **Forces increasing risk**: The new clade Ib variant is more transmissible and severe, and there is a risk of imported cases. The outbreak in Africa is worsening, with increasing cases and deaths.
   - **Forces decreasing risk**: The US has no direct flights from the DRC, and the CDC has robust surveillance and response systems. Vaccination coverage among high-risk groups in the US is relatively high.

6. **Extrapolate current trends linearly**:
   - The current trend shows a worsening outbreak in Africa but no significant spread to the US. The CDC has not indicated any imminent change in its risk assessment.

7. **Distinguish degrees of doubt**:
   - There is a small but non-zero chance that the situation could change rapidly, such as if a case is detected in the US or if the outbreak spreads to countries with more travel connections to the US.

8. **Balance under- and overconfidence**:
   - While the current risk is low, the possibility of a rapid change in the situation warrants some caution. However, the likelihood of the CDC revising its assessment to "Moderate" or higher before October 1, 2024, is low.

9. **Look for errors behind mistakes**:
   - Overestimating the risk based on the severity of the outbreak in Africa without considering the US's specific context could lead to an overconfident prediction.

**Conclusion**: Based on the current CDC assessment, the lack of significant spread outside Africa, and the US's robust public health infrastructure, the likelihood of the CDC revising its risk assessment to exceed "Low" before October 1, 2024, is low. However, the possibility of imported cases or a rapid change in the situation warrants a small probability.

My Prediction: Between 5.00% and 15.00%, but 10.00% being the most likely. Probability: 10.00%.

2025-01-04 13:48:35,212 - INFO - Run 3:
To forecast whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "Low" before October 1, 2024, I will follow the superforecasting principles outlined:

1. **Triage and reference relevant predictions**: No specific human predictions from platforms like FiveThirtyEight, Polymarket, or Metaculus are available for this question, so I will rely on the provided data and historical patterns.

2. **Break the problem into sub-problems**:
   - What is the current CDC assessment of mpox risk to the US general public?
   - What factors could cause the CDC to revise its risk assessment upward?
   - What is the likelihood of these factors occurring before October 1, 2024?

3. **Balance inside and outside views**:
   - **Outside view**: Historically, the CDC has maintained a "Very Low" or "Low" risk assessment for mpox in the US general population, even during the 2022 outbreak. The current outbreak in Africa, while severe, has not yet led to significant spread outside the continent.
   - **Inside view**: The new clade Ib variant is more transmissible and severe, but the US has no direct flights from the DRC, and the CDC has assessed the risk as "Very Low" with moderate confidence. The US also has a robust public health infrastructure and vaccination programs in place.

4. **Balance under- and overreacting to evidence**:
   - The Africa CDC has declared a public health emergency of continental security, and the WHO has declared a global public health emergency. However, the CDC's assessment remains "Very Low" for the US general population.
   - The European CDC and other health agencies have assessed the risk to their general populations as "Very Low" or "Low," suggesting a low likelihood of significant spread to the US.

5. **Clashing causal forces**:
   - **Forces increasing risk**: The new clade Ib variant is more transmissible and severe, and there is a risk of imported cases. The outbreak in Africa is worsening, with increasing cases and deaths.
   - **Forces decreasing risk**: The US has no direct flights from the DRC, and the CDC has robust surveillance and response systems. Vaccination coverage among high-risk groups in the US is relatively high.

6. **Extrapolate current trends linearly**:
   - The current trend shows a worsening outbreak in Africa but no significant spread to the US. The CDC has not indicated any imminent change in its risk assessment.

7. **Distinguish degrees of doubt**:
   - There is a small but non-zero chance that the situation could change rapidly, such as if a case is detected in the US or if the outbreak spreads to countries with more travel connections to the US.

8. **Balance under- and overconfidence**:
   - While the current risk is low, the possibility of a rapid change in the situation warrants some caution. However, the likelihood of the CDC revising its assessment to "Moderate" or higher before October 1, 2024, is low.

9. **Look for errors behind mistakes**:
   - Overestimating the risk based on the severity of the outbreak in Africa without considering the US's specific context could lead to an overconfident prediction.

**Conclusion**: Based on the current CDC assessment, the lack of significant spread outside Africa, and the US's robust public health infrastructure, the likelihood of the CDC revising its risk assessment to exceed "Low" before October 1, 2024, is low. However, the possibility of imported cases or a rapid change in the situation warrants a small probability.

My Prediction: Between 5.00% and 15.00%, but 10.00% being the most likely. Probability: 10.00%.

2025-01-04 13:48:35,212 - INFO - Run 3:
To forecast whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "Low" before October 1, 2024, I will follow the superforecasting principles outlined:

1. **Triage and reference relevant predictions**: No specific human predictions from platforms like FiveThirtyEight, Polymarket, or Metaculus are available for this question, so I will rely on the provided data and historical patterns.

2. **Break the problem into sub-problems**:
   - What is the current CDC assessment of mpox risk to the US general public?
   - What factors could cause the CDC to revise its risk assessment upward?
   - What is the likelihood of these factors occurring before October 1, 2024?

3. **Balance inside and outside views**:
   - **Outside view**: Historically, the CDC has maintained a "Very Low" or "Low" risk assessment for mpox in the US general population, even during the 2022 outbreak. The current outbreak in Africa, while severe, has not yet led to significant spread outside the continent.
   - **Inside view**: The new clade Ib variant is more transmissible and severe, but the US has no direct flights from the DRC, and the CDC has assessed the risk as "Very Low" with moderate confidence. The US also has a robust public health infrastructure and vaccination programs in place.

4. **Balance under- and overreacting to evidence**:
   - The Africa CDC has declared a public health emergency of continental security, and the WHO has declared a global public health emergency. However, the CDC's assessment remains "Very Low" for the US general population.
   - The European CDC and other health agencies have assessed the risk to their general populations as "Very Low" or "Low," suggesting a low likelihood of significant spread to the US.

5. **Clashing causal forces**:
   - **Forces increasing risk**: The new clade Ib variant is more transmissible and severe, and there is a risk of imported cases. The outbreak in Africa is worsening, with increasing cases and deaths.
   - **Forces decreasing risk**: The US has no direct flights from the DRC, and the CDC has robust surveillance and response systems. Vaccination coverage among high-risk groups in the US is relatively high.

6. **Extrapolate current trends linearly**:
   - The current trend shows a worsening outbreak in Africa but no significant spread to the US. The CDC has not indicated any imminent change in its risk assessment.

7. **Distinguish degrees of doubt**:
   - There is a small but non-zero chance that the situation could change rapidly, such as if a case is detected in the US or if the outbreak spreads to countries with more travel connections to the US.

8. **Balance under- and overconfidence**:
   - While the current risk is low, the possibility of a rapid change in the situation warrants some caution. However, the likelihood of the CDC revising its assessment to "Moderate" or higher before October 1, 2024, is low.

9. **Look for errors behind mistakes**:
   - Overestimating the risk based on the severity of the outbreak in Africa without considering the US's specific context could lead to an overconfident prediction.

**Conclusion**: Based on the current CDC assessment, the lack of significant spread outside Africa, and the US's robust public health infrastructure, the likelihood of the CDC revising its risk assessment to exceed "Low" before October 1, 2024, is low. However, the possibility of imported cases or a rapid change in the situation warrants a small probability.

My Prediction: Between 5.00% and 15.00%, but 10.00% being the most likely. Probability: 10.00%.

2025-01-04 13:49:01,384 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Low" before October 1, 2024?
2025-01-04 13:49:01,384 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Low" before October 1, 2024?
2025-01-04 13:49:01,384 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Low" before October 1, 2024?
2025-01-04 13:49:01,384 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Low" before October 1, 2024?
2025-01-04 13:49:01,384 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Low" before October 1, 2024?
2025-01-04 13:49:01,385 - INFO - Run 4:
To forecast whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "Low" before October 1, 2024, I will follow the superforecasting principles outlined:

1. **Triage and reference relevant predictions**: There are no specific market predictions or forecasts from platforms like Polymarket or Metaculus for this exact question, so I will rely on the available evidence and base rates.

2. **Break the problem into sub-problems**:
   - What is the current CDC assessment of mpox risk to the US general public?
   - What are the key drivers of mpox transmission and spread globally and in the US?
   - What are the trends in mpox cases and outbreaks, particularly in Africa and Europe?
   - What are the potential pathways for mpox to spread to the US, and how likely are they?

3. **Strike the right balance between inside and outside views**:
   - **Outside view**: Historically, mpox outbreaks outside of Africa have been limited and controlled, with the 2022 outbreak being an exception. The CDC has consistently assessed the risk to the US general public as "Low" or "Very Low" during previous outbreaks.
   - **Inside view**: The current outbreak in Africa, driven by the more transmissible and severe clade Ib, has led to a global public health emergency declaration by the WHO. However, the CDC has maintained a "Very Low" risk assessment for the US general public as of August 14, 2024, citing limited travel and no direct flights from affected regions.

4. **Strike the right balance between under- and overreacting to evidence**:
   - The outbreak in Africa is severe, with a 160% increase in cases and 19% increase in deaths in 2024 compared to 2023. However, the CDC has noted that the risk to the US remains low due to limited travel and no direct flights from affected regions.
   - The European CDC has assessed the risk to Europe as "Very Low," and no significant spread has been reported outside of Africa. This suggests that the likelihood of mpox spreading to the US is low.

5. **Look for clashing causal forces**:
   - **Forces increasing risk**: The new clade Ib is more transmissible and severe, and there is a global public health emergency. Cross-border movement and limited vaccine availability in Africa could increase the risk of spread.
   - **Forces decreasing risk**: The US has no direct flights from affected regions, and the CDC has maintained a low risk assessment. The US also has a robust public health infrastructure and access to vaccines.

6. **Extrapolate current trends linearly**:
   - The current trend shows a significant outbreak in Africa but limited spread outside the continent. The CDC has not indicated any change in its risk assessment, and there is no evidence of sustained transmission in the US.

7. **Distinguish degrees of doubt**:
   - There is a small chance that the outbreak could spread to the US through indirect travel or other pathways, but this is unlikely given the current evidence.

8. **Strike the right balance between under- and overconfidence**:
   - While the outbreak in Africa is concerning, the CDC's current assessment and the lack of spread to the US suggest that the risk is low. However, there is always some uncertainty, so I will not assign a probability of 0%.

9. **Look for errors behind mistakes**:
   - The main risk is overreacting to the severity of the outbreak in Africa without considering the barriers to spread to the US. The CDC's assessment is based on these barriers, so I will not overadjust my forecast.

**Conclusion**: Based on the current evidence, the CDC is likely to maintain its "Low" or "Very Low" risk assessment for the US general public. The outbreak in Africa is severe, but the lack of direct travel and robust public health measures in the US make it unlikely that the risk assessment will exceed "Low" before October 1, 2024.

My Prediction: Between 5.00% and 15.00%, but 10.00% being the most likely. Probability: 10.00%.

2025-01-04 13:49:01,385 - INFO - Run 4:
To forecast whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "Low" before October 1, 2024, I will follow the superforecasting principles outlined:

1. **Triage and reference relevant predictions**: There are no specific market predictions or forecasts from platforms like Polymarket or Metaculus for this exact question, so I will rely on the available evidence and base rates.

2. **Break the problem into sub-problems**:
   - What is the current CDC assessment of mpox risk to the US general public?
   - What are the key drivers of mpox transmission and spread globally and in the US?
   - What are the trends in mpox cases and outbreaks, particularly in Africa and Europe?
   - What are the potential pathways for mpox to spread to the US, and how likely are they?

3. **Strike the right balance between inside and outside views**:
   - **Outside view**: Historically, mpox outbreaks outside of Africa have been limited and controlled, with the 2022 outbreak being an exception. The CDC has consistently assessed the risk to the US general public as "Low" or "Very Low" during previous outbreaks.
   - **Inside view**: The current outbreak in Africa, driven by the more transmissible and severe clade Ib, has led to a global public health emergency declaration by the WHO. However, the CDC has maintained a "Very Low" risk assessment for the US general public as of August 14, 2024, citing limited travel and no direct flights from affected regions.

4. **Strike the right balance between under- and overreacting to evidence**:
   - The outbreak in Africa is severe, with a 160% increase in cases and 19% increase in deaths in 2024 compared to 2023. However, the CDC has noted that the risk to the US remains low due to limited travel and no direct flights from affected regions.
   - The European CDC has assessed the risk to Europe as "Very Low," and no significant spread has been reported outside of Africa. This suggests that the likelihood of mpox spreading to the US is low.

5. **Look for clashing causal forces**:
   - **Forces increasing risk**: The new clade Ib is more transmissible and severe, and there is a global public health emergency. Cross-border movement and limited vaccine availability in Africa could increase the risk of spread.
   - **Forces decreasing risk**: The US has no direct flights from affected regions, and the CDC has maintained a low risk assessment. The US also has a robust public health infrastructure and access to vaccines.

6. **Extrapolate current trends linearly**:
   - The current trend shows a significant outbreak in Africa but limited spread outside the continent. The CDC has not indicated any change in its risk assessment, and there is no evidence of sustained transmission in the US.

7. **Distinguish degrees of doubt**:
   - There is a small chance that the outbreak could spread to the US through indirect travel or other pathways, but this is unlikely given the current evidence.

8. **Strike the right balance between under- and overconfidence**:
   - While the outbreak in Africa is concerning, the CDC's current assessment and the lack of spread to the US suggest that the risk is low. However, there is always some uncertainty, so I will not assign a probability of 0%.

9. **Look for errors behind mistakes**:
   - The main risk is overreacting to the severity of the outbreak in Africa without considering the barriers to spread to the US. The CDC's assessment is based on these barriers, so I will not overadjust my forecast.

**Conclusion**: Based on the current evidence, the CDC is likely to maintain its "Low" or "Very Low" risk assessment for the US general public. The outbreak in Africa is severe, but the lack of direct travel and robust public health measures in the US make it unlikely that the risk assessment will exceed "Low" before October 1, 2024.

My Prediction: Between 5.00% and 15.00%, but 10.00% being the most likely. Probability: 10.00%.

2025-01-04 13:49:01,385 - INFO - Run 4:
To forecast whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "Low" before October 1, 2024, I will follow the superforecasting principles outlined:

1. **Triage and reference relevant predictions**: There are no specific market predictions or forecasts from platforms like Polymarket or Metaculus for this exact question, so I will rely on the available evidence and base rates.

2. **Break the problem into sub-problems**:
   - What is the current CDC assessment of mpox risk to the US general public?
   - What are the key drivers of mpox transmission and spread globally and in the US?
   - What are the trends in mpox cases and outbreaks, particularly in Africa and Europe?
   - What are the potential pathways for mpox to spread to the US, and how likely are they?

3. **Strike the right balance between inside and outside views**:
   - **Outside view**: Historically, mpox outbreaks outside of Africa have been limited and controlled, with the 2022 outbreak being an exception. The CDC has consistently assessed the risk to the US general public as "Low" or "Very Low" during previous outbreaks.
   - **Inside view**: The current outbreak in Africa, driven by the more transmissible and severe clade Ib, has led to a global public health emergency declaration by the WHO. However, the CDC has maintained a "Very Low" risk assessment for the US general public as of August 14, 2024, citing limited travel and no direct flights from affected regions.

4. **Strike the right balance between under- and overreacting to evidence**:
   - The outbreak in Africa is severe, with a 160% increase in cases and 19% increase in deaths in 2024 compared to 2023. However, the CDC has noted that the risk to the US remains low due to limited travel and no direct flights from affected regions.
   - The European CDC has assessed the risk to Europe as "Very Low," and no significant spread has been reported outside of Africa. This suggests that the likelihood of mpox spreading to the US is low.

5. **Look for clashing causal forces**:
   - **Forces increasing risk**: The new clade Ib is more transmissible and severe, and there is a global public health emergency. Cross-border movement and limited vaccine availability in Africa could increase the risk of spread.
   - **Forces decreasing risk**: The US has no direct flights from affected regions, and the CDC has maintained a low risk assessment. The US also has a robust public health infrastructure and access to vaccines.

6. **Extrapolate current trends linearly**:
   - The current trend shows a significant outbreak in Africa but limited spread outside the continent. The CDC has not indicated any change in its risk assessment, and there is no evidence of sustained transmission in the US.

7. **Distinguish degrees of doubt**:
   - There is a small chance that the outbreak could spread to the US through indirect travel or other pathways, but this is unlikely given the current evidence.

8. **Strike the right balance between under- and overconfidence**:
   - While the outbreak in Africa is concerning, the CDC's current assessment and the lack of spread to the US suggest that the risk is low. However, there is always some uncertainty, so I will not assign a probability of 0%.

9. **Look for errors behind mistakes**:
   - The main risk is overreacting to the severity of the outbreak in Africa without considering the barriers to spread to the US. The CDC's assessment is based on these barriers, so I will not overadjust my forecast.

**Conclusion**: Based on the current evidence, the CDC is likely to maintain its "Low" or "Very Low" risk assessment for the US general public. The outbreak in Africa is severe, but the lack of direct travel and robust public health measures in the US make it unlikely that the risk assessment will exceed "Low" before October 1, 2024.

My Prediction: Between 5.00% and 15.00%, but 10.00% being the most likely. Probability: 10.00%.

2025-01-04 13:49:01,385 - INFO - Run 4:
To forecast whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "Low" before October 1, 2024, I will follow the superforecasting principles outlined:

1. **Triage and reference relevant predictions**: There are no specific market predictions or forecasts from platforms like Polymarket or Metaculus for this exact question, so I will rely on the available evidence and base rates.

2. **Break the problem into sub-problems**:
   - What is the current CDC assessment of mpox risk to the US general public?
   - What are the key drivers of mpox transmission and spread globally and in the US?
   - What are the trends in mpox cases and outbreaks, particularly in Africa and Europe?
   - What are the potential pathways for mpox to spread to the US, and how likely are they?

3. **Strike the right balance between inside and outside views**:
   - **Outside view**: Historically, mpox outbreaks outside of Africa have been limited and controlled, with the 2022 outbreak being an exception. The CDC has consistently assessed the risk to the US general public as "Low" or "Very Low" during previous outbreaks.
   - **Inside view**: The current outbreak in Africa, driven by the more transmissible and severe clade Ib, has led to a global public health emergency declaration by the WHO. However, the CDC has maintained a "Very Low" risk assessment for the US general public as of August 14, 2024, citing limited travel and no direct flights from affected regions.

4. **Strike the right balance between under- and overreacting to evidence**:
   - The outbreak in Africa is severe, with a 160% increase in cases and 19% increase in deaths in 2024 compared to 2023. However, the CDC has noted that the risk to the US remains low due to limited travel and no direct flights from affected regions.
   - The European CDC has assessed the risk to Europe as "Very Low," and no significant spread has been reported outside of Africa. This suggests that the likelihood of mpox spreading to the US is low.

5. **Look for clashing causal forces**:
   - **Forces increasing risk**: The new clade Ib is more transmissible and severe, and there is a global public health emergency. Cross-border movement and limited vaccine availability in Africa could increase the risk of spread.
   - **Forces decreasing risk**: The US has no direct flights from affected regions, and the CDC has maintained a low risk assessment. The US also has a robust public health infrastructure and access to vaccines.

6. **Extrapolate current trends linearly**:
   - The current trend shows a significant outbreak in Africa but limited spread outside the continent. The CDC has not indicated any change in its risk assessment, and there is no evidence of sustained transmission in the US.

7. **Distinguish degrees of doubt**:
   - There is a small chance that the outbreak could spread to the US through indirect travel or other pathways, but this is unlikely given the current evidence.

8. **Strike the right balance between under- and overconfidence**:
   - While the outbreak in Africa is concerning, the CDC's current assessment and the lack of spread to the US suggest that the risk is low. However, there is always some uncertainty, so I will not assign a probability of 0%.

9. **Look for errors behind mistakes**:
   - The main risk is overreacting to the severity of the outbreak in Africa without considering the barriers to spread to the US. The CDC's assessment is based on these barriers, so I will not overadjust my forecast.

**Conclusion**: Based on the current evidence, the CDC is likely to maintain its "Low" or "Very Low" risk assessment for the US general public. The outbreak in Africa is severe, but the lack of direct travel and robust public health measures in the US make it unlikely that the risk assessment will exceed "Low" before October 1, 2024.

My Prediction: Between 5.00% and 15.00%, but 10.00% being the most likely. Probability: 10.00%.

2025-01-04 13:49:01,385 - INFO - Run 4:
To forecast whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "Low" before October 1, 2024, I will follow the superforecasting principles outlined:

1. **Triage and reference relevant predictions**: There are no specific market predictions or forecasts from platforms like Polymarket or Metaculus for this exact question, so I will rely on the available evidence and base rates.

2. **Break the problem into sub-problems**:
   - What is the current CDC assessment of mpox risk to the US general public?
   - What are the key drivers of mpox transmission and spread globally and in the US?
   - What are the trends in mpox cases and outbreaks, particularly in Africa and Europe?
   - What are the potential pathways for mpox to spread to the US, and how likely are they?

3. **Strike the right balance between inside and outside views**:
   - **Outside view**: Historically, mpox outbreaks outside of Africa have been limited and controlled, with the 2022 outbreak being an exception. The CDC has consistently assessed the risk to the US general public as "Low" or "Very Low" during previous outbreaks.
   - **Inside view**: The current outbreak in Africa, driven by the more transmissible and severe clade Ib, has led to a global public health emergency declaration by the WHO. However, the CDC has maintained a "Very Low" risk assessment for the US general public as of August 14, 2024, citing limited travel and no direct flights from affected regions.

4. **Strike the right balance between under- and overreacting to evidence**:
   - The outbreak in Africa is severe, with a 160% increase in cases and 19% increase in deaths in 2024 compared to 2023. However, the CDC has noted that the risk to the US remains low due to limited travel and no direct flights from affected regions.
   - The European CDC has assessed the risk to Europe as "Very Low," and no significant spread has been reported outside of Africa. This suggests that the likelihood of mpox spreading to the US is low.

5. **Look for clashing causal forces**:
   - **Forces increasing risk**: The new clade Ib is more transmissible and severe, and there is a global public health emergency. Cross-border movement and limited vaccine availability in Africa could increase the risk of spread.
   - **Forces decreasing risk**: The US has no direct flights from affected regions, and the CDC has maintained a low risk assessment. The US also has a robust public health infrastructure and access to vaccines.

6. **Extrapolate current trends linearly**:
   - The current trend shows a significant outbreak in Africa but limited spread outside the continent. The CDC has not indicated any change in its risk assessment, and there is no evidence of sustained transmission in the US.

7. **Distinguish degrees of doubt**:
   - There is a small chance that the outbreak could spread to the US through indirect travel or other pathways, but this is unlikely given the current evidence.

8. **Strike the right balance between under- and overconfidence**:
   - While the outbreak in Africa is concerning, the CDC's current assessment and the lack of spread to the US suggest that the risk is low. However, there is always some uncertainty, so I will not assign a probability of 0%.

9. **Look for errors behind mistakes**:
   - The main risk is overreacting to the severity of the outbreak in Africa without considering the barriers to spread to the US. The CDC's assessment is based on these barriers, so I will not overadjust my forecast.

**Conclusion**: Based on the current evidence, the CDC is likely to maintain its "Low" or "Very Low" risk assessment for the US general public. The outbreak in Africa is severe, but the lack of direct travel and robust public health measures in the US make it unlikely that the risk assessment will exceed "Low" before October 1, 2024.

My Prediction: Between 5.00% and 15.00%, but 10.00% being the most likely. Probability: 10.00%.

